根据儿科专用计划进行的临床试验的经济回报
Jennifer S Li1, Eric L Eisenstein, Henry G Grabowski
1Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, NC 27705, USA. jennifer.li@duke.edu
JAMA
|February 8, 2007
概括
儿科专用计划为完成儿科试验的制药公司提供可变的经济回报. 虽然一些试验带来了显著的利,但其他试验则提供了更适度的投资回报.
科学领域:
- 制药政策 制药政策
- 儿科临床试验儿童临床试验
- 药物开发经济学 药物开发经济学
背景情况:
- 美国食品和药物管理局 (FDA) 儿科独家计划为完成儿科试验授予6个月的营销延期.
- 该计划鼓励儿科研究,但面临着对制药行业的经济利益的批评.
研究的目的:
- 量化参与儿科专用计划的制药公司的经济回报.
- 评估完成FDA要求的儿科临床试验的财务影响.
主要方法:
- 一项队列研究分析了九种获得儿科专用权的药物.
- 儿科试验的成本被估计为税后现金流出.
- 市场销售预计将估计税后现金流入从六个月的独家延期.
主要成果:
- 经济回报差异很大,净回报范围从 - 890万美元到 5079万美元.
- 收益/成本比率也显示出很大的变化,从-0.68到73.63.
- 研究的症状包括喘,多动症,癌症和糖尿病.
结论:
- 儿科专用性为开展儿科临床试验提供了可变的经济激励.
- 该计划可以带来非常有利可图的结果或对药物赞助商的更有限的回报.
相关概念视频
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
